Nomogram Could Aid Clinical Decision-Making for Gastroenteropancreatic Neuroendocrine Tumors
The nomogram proved more accurate than TNM staging for predicting 3-year and 5-year overall survival.
Endocrine Cancer
How to Prevent a Cyberattack from Derailing Cancer Care
Cyberattacks on health care organizations may not be fully preventable, but there are ways to limit their impact on cancer care.
‘Practice-Changing’ Results With Sunitinib in Malignant Pheochromocytoma and Paraganglioma
The 12-month progression-free survival rate was 35.9% with sunitinib and 18.9% with placebo.
Cabometyx Approved for Radioactive Iodine-Refractory Differentiated Thyroid Cancer
The approval was based on data from the phase 3 COSMIC-311 study.
Multifocality Appears to Increase Risk of Recurrence in Papillary Thyroid Carcinoma
The risk of recurrence varied by patient age, tumor size, and number of foci.
Vorinostat Plus MIBG Proves More Effective Than Other MIBG Regimens in Relapsed or Refractory Neuroblastoma
Response rates were highest with MIBG plus vorinostat.
‘Excellent’ Outcomes and Room for Improvement in Pediatric Adrenocortical Carcinoma
Patients with stage II or IV disease did not fare as well as patients with stage I or III disease.
Study Reveals Less Toxic Induction Regimen for High-Risk Neuroblastoma
The rCOJEC regimen was less toxic than the MSKCC-N5 regimen.
Response Endpoints Deemed ‘Poor Surrogates’ for Overall Survival in Trials of Immune Checkpoint Inhibitors
Response endpoints were not strongly correlated with overall survival at the trial level.
Vandetanib and Cabozantinib Deemed Effective in Real-World Study of Medullary Thyroid Cancer
The overall survival rate at 1 year was 86% with vandetanib and 70% with cabozantinib.
- Loading...
Loading...
Next post in Endocrine Cancer
Loading... 
Loading...